English (United States)
|
Italiano (Italia)
Contacts
|
Rss
Search
Search
English (United States)
|
Italiano (Italia)
Home
Who we are
Mission and strategy
Structure and management
News and events
Press review
Farmindustria bulletin
Photo gallery
Video gallery
The group
Our offices
The group in figures
Activities
Research and development
Pre-clinical development
Clinical development
Clinical trial transparency
Medical affairs
Regulatory affairs
Scientific publications
Pre-clinical
Pre-approval
Post-approval
Pharmaceutical manufacturing
Business development
Licensing
Pipeline
About muscular distrophies
Duchenne and Becker MD
Givinostat
Mieloproliferative Neoplasms
Polycythemia Vera (PV)
Clinical trials
Givinostat for DMD
Givinostat for BMD - ITF BECKER
Givinostat for Polycythemia Vera (PV)
Therapeutic areas
Thrombosis and critical ischemia
Drugs
Food supplements
Cardiovascular, osteoporosis and inflammation
Drugs
Immuno-oncology
Drugs
Gynecology
Drugs
Food supplements
Medical devices
Neurology and psychiatry
Drugs
Food supplements
Responsibilities
Pharmacovigilance
Patients association
Transparency
Safety policy
Organization
Home
Who we are
- Mission and strategy
- Structure and management
- News and events
- Press review
- Farmindustria bulletin
- Photo gallery
- Video gallery
The group
- Our offices
- The group in figures
Activities
- Research and development
- - Pre-clinical development
- - Clinical development
- - Clinical trial transparency
- - Medical affairs
- - Regulatory affairs
- Scientific publications
- - Pre-clinical
- - Pre-approval
- - Post-approval
- Pharmaceutical manufacturing
- Business development
- Licensing
- Pipeline
- - About muscular distrophies
- - - Duchenne and Becker MD
- - - Givinostat
- - Mieloproliferative Neoplasms
- - - Polycythemia Vera (PV)
- - Clinical trials
- - - Givinostat for DMD
- - - Givinostat for BMD - ITF BECKER
- - - Givinostat for Polycythemia Vera (PV)
Therapeutic areas
- Thrombosis and critical ischemia
- - Drugs
- - Food supplements
- Cardiovascular, osteoporosis and inflammation
- - Drugs
- Immuno-oncology
- - Drugs
- Gynecology
- - Drugs
- - Food supplements
- - Medical devices
- Neurology and psychiatry
- - Drugs
- - Food supplements
Responsibilities
- Pharmacovigilance
- Patients association
- Transparency
- Safety policy
Organization
Home
>>
Who we are
>>
Press review
>>
Article details
Back
Home
Who we are
Mission and strategy
Structure and management
News and events
Press review
Farmindustria bulletin
Photo gallery
Video gallery
The group
Our offices
The group in figures
Activities
Research and development
Pre-clinical development
Clinical development
Clinical trial transparency
Medical affairs
Regulatory affairs
Scientific publications
Pre-clinical
Pre-approval
Post-approval
Pharmaceutical manufacturing
Business development
Licensing
Pipeline
About muscular distrophies
Duchenne and Becker MD
Givinostat
Mieloproliferative Neoplasms
Polycythemia Vera (PV)
Clinical trials
Givinostat for DMD
Givinostat for BMD - ITF BECKER
Givinostat for Polycythemia Vera (PV)
Therapeutic areas
Thrombosis and critical ischemia
Drugs
Food supplements
Cardiovascular, osteoporosis and inflammation
Drugs
Immuno-oncology
Drugs
Gynecology
Drugs
Food supplements
Medical devices
Neurology and psychiatry
Drugs
Food supplements
Responsibilities
Pharmacovigilance
Patients association
Transparency
Safety policy
Organization
Article details
25 March 2015 - Pharmakronos
L'accordo Chemi-Teva dà i suoi frutti
Link to the article